Extensive surgeries, including debulking procedures, after first-line imatinib therapy have been shown to extend OS in selected KIT/PDGFRA-mutant GIST patients with locally advanced (unresectable at diagnosis but not metastatic) and/or metastatic disease.23,24 Therefore, it is conceivable that, given the high response rate achieved with avapritinib in PDGFRA D842V-mutant GISTs, these types of surgical procedures may also be feasible in this subset of patients and obtain similar positive outcomes thus potentially expanding the survival in this population. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.